The webinar was performed by the professor and director of the Glasgow Epilepsy Unit in Scotland, Dr. Martin Brodie. Photo: Disclosure.
Prati-Dronaduzzi, located in the western region of Paraná, is a benchmark in the production of medicines in Brazil. The new moment of the pharmaceutical industry, in the area of Medical Prescription, also shows the commitment to offer professionals technical and scientific information. In line with this concept, the industry has just supported an international webinar.
Held by the Brazilian League of Epilepsy (LBE), the continuing medical education meeting was performed by the professor and director of the Glasgow Epilepsy Unit in Scotland, Dr. Martin Brodie, with the moderation of the president of LBE, Dr. Kette Vallente and medical consultant at Prati-Donaduzzi, Dr. Eduardo Motti. With the theme: “Drug resistant epilepsy: where are we now?” The event brought together virtually over 200 physicians from different specialties.
During the event, the lecturer shared clinical cases and experiences with prescription drugs with the participants. Currently, Dr. Brodie is the president of the International Bureau for Epilepsy – IBE. In addition, he has published over 500 editorials, chapters, reviews and scientific articles on the subject.
According to the director of Medical Prescription at Prati-Donaduzzi, Edilson Bianqui, the moment of discussion contributes to an important exchange of experiences among professionals.
“We have a great commitment to the health of Brazilians. Support for the webinar is a way of contributing to updating professionals with technical and scientific information. Investing in the training of the professionals generates reflexes for the population”, evaluates the director.
Evolution for Life
In addition to supporting the webinar, the industry holds a series of meetings that make it possible to share knowledge about the regulatory aspects of Brazil, technical and scientific information on the first and only national product of Cannabidiol. So far, 26 editions have been held and more than 1,300 professionals from different specialties participated.
Recently, the pharmaceutical company launched a website (https://www.evolucaoparavida.com.br/) where doctors find an exclusive area with information on various pathologies, clinical cases, scientific articles, virtual symposia and Prati-Donaduzzi branded product portfolio.
“The website allows the physician to have access to free, quality and interesting content at any time he/she prefers. In addition, the population will also have health information”, says Bianqui.
Central Nervous System
The pharmaceutical industry will have 22 new branded drugs, most of which are aimed at the Central Nervous System (CNS) and indicated to treat diseases such as epilepsy, Parkinson's, Alzheimer's, anxiety, depression, neuropathic pain, schizophrenia, autism, bipolar disorder and insomnia.
Prati-Donaduzzi, a Brazilian pharmaceutical industry, is specialized and a benchmark in the development and production of generic drugs. Headquartered in Toledo, Western Paraná, it produces approximately 12 billion therapeutic doses per year and generates more than 4,500 employments. The industry has one of the largest generic drug portfolios in Brazil and it has been working in the area of Medical Prescriptions since 2019.